What is the difference between Ogivri and Herceptin?
Ogivri (trastuzumab-dkst) is a biosimilar to Herceptin (trastuzumab).
A biosimilar is a biological product that is FDA-approved and highly similar to a biologic already FDA-approved with no clinically meaningful differences in terms of safety and effectiveness from the reference product.
What Are Biosimilars? Top Facts You May Not Know
Ogivri and Herceptin are both used for the treatment of patients with HER2+ breast cancer or HER2-overexpressing metastatic stomach cancer (metastatic gastric or gastroesophageal junction adenocarcinoma).
Ogivri has not been approved as an interchangeable biosimilar, meaning the pharmacist cannot substitute Ogivri for Herceptin without consulting the prescriber.
Ogivri was the first approved biosimilar to Herceptin.
Herceptin (trastuzumab) Biosimilars
Read next
Related medical questions
- What happens after Herceptin treatment?
- How long can I stay on Herceptin?
- What are the biosimilars of Herceptin?
- What biosimilars have been approved in the United States?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
- What is a biologic drug?
- How long does Herceptin stay in your body?
- How do Herceptin (trastuzumab) and Perjeta (pertuzumab) work together?
- How effective is Herceptin for Breast & Gastric Cancer?
- What is the difference between Herceptin and Herceptin Hylecta?
- Does Herceptin (trastuzumab) stop menstrual periods?
- Do Herceptin (trastuzumab) injections hurt?
- What is the difference between Herzuma and Herceptin?
- How is Herceptin Injection and Herceptin Hylecta administered?
Drug information
Related support groups
- Herceptin (19 questions, 32 members)
- Trastuzumab (14 questions, 4 members)
- Ogivri (4 questions, 4 members)
- Breast Cancer (120 questions, 304 members)
- Gastric Cancer (11 questions, 12 members)
